• LAST PRICE
    7.3000
  • TODAY'S CHANGE (%)
    Trending Up0.2000 (2.8169%)
  • Bid / Lots
    6.0600/ 1
  • Ask / Lots
    7.6000/ 11
  • Open / Previous Close
    7.0700 / 7.1000
  • Day Range
    Low 6.9500
    High 7.3100
  • 52 Week Range
    Low 5.3100
    High 46.9099
  • Volume
    285,044
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.1
TimeVolumeAVIR
09:32 ET36417.05
09:34 ET27327.08
09:36 ET1007.1
09:38 ET2707.11
09:39 ET1007.09
09:41 ET10237.13
09:45 ET4007.18
09:48 ET46007.2005
09:50 ET2007.17
09:52 ET7367.23
09:54 ET8247.25
09:56 ET5007.23
10:01 ET1007.26
10:03 ET5007.22
10:06 ET13007.18
10:08 ET7007.19
10:12 ET7007.18
10:17 ET2007.15
10:19 ET2007.18
10:21 ET11007.16
10:26 ET1007.15
10:28 ET10207.14
10:32 ET15887.15
10:33 ET14247.18
10:35 ET1007.195
10:39 ET10187.17
10:42 ET5907.13
10:44 ET6407.18
10:46 ET118707.18
10:48 ET10007.18
10:50 ET4297.19
10:51 ET3537.15
10:53 ET3007.165
10:55 ET3007.16
10:57 ET4457.1618
11:00 ET9007.17
11:02 ET1007.16
11:04 ET5007.13
11:06 ET6007.16
11:08 ET2007.17
11:09 ET5007.2
11:13 ET3007.19
11:15 ET4007.2
11:18 ET1007.21
11:20 ET6327.19
11:22 ET1007.18
11:24 ET2007.19
11:26 ET1007.19
11:27 ET3257.19
11:29 ET2007.18
11:33 ET2007.18
11:36 ET5007.19
11:38 ET2007.2
11:40 ET4137.2
11:44 ET11007.21
11:45 ET2007.19
11:51 ET5007.16
11:54 ET1007.14
11:56 ET1007.14
11:58 ET1007.15
12:00 ET5007.15
12:02 ET9007.13
12:03 ET3007.1
12:05 ET1987.11
12:07 ET2007.1
12:09 ET2007.11
12:12 ET4007.1
12:14 ET2007.09
12:16 ET4007.1
12:18 ET9007.11
12:20 ET10387.14
12:21 ET1507.14
12:23 ET2007.13
12:25 ET3007.12
12:27 ET9007.14
12:30 ET8007.16
12:36 ET2007.135
12:39 ET2007.11
12:43 ET7307.1
12:45 ET1007.07
12:48 ET1007.06
12:50 ET7557.06
12:52 ET6007.08
12:54 ET3007.08
12:57 ET12207.07
01:03 ET5007.05
01:06 ET1007.05
01:08 ET6007.03
01:10 ET10007.02
01:12 ET49967.07
01:14 ET12727.1
01:17 ET8207.11
01:19 ET10007.12
01:21 ET2007.12
01:24 ET36227.13
01:26 ET28857.1216
01:28 ET11167.12
01:32 ET4987.14
01:35 ET1007.14
01:37 ET2007.1446
01:39 ET1007.15
01:48 ET12507.16
01:50 ET3007.17
01:51 ET1007.17
01:55 ET6007.16
01:57 ET10037.17
02:00 ET4067.17
02:02 ET2007.18
02:04 ET107927.11
02:06 ET12137.12
02:09 ET4007.11
02:11 ET5957.1
02:15 ET28007.11
02:20 ET4137.12
02:24 ET9807.14
02:26 ET1007.17
02:27 ET14187.15
02:36 ET1007.15
02:38 ET3007.16
02:40 ET10007.17
02:42 ET1007.16
02:44 ET32007.177
02:45 ET2007.18
02:47 ET7007.19
02:49 ET4007.2
02:51 ET7007.195
02:54 ET6617.19
02:56 ET10537.18
03:00 ET2007.19
03:02 ET1007.19
03:03 ET4007.19
03:05 ET13007.165
03:07 ET6007.17
03:09 ET6217.2
03:12 ET8007.21
03:14 ET2007.2
03:16 ET10207.2
03:18 ET20907.2
03:21 ET7057.19
03:23 ET2007.17
03:25 ET13007.19
03:27 ET5007.2
03:30 ET8367.21
03:32 ET19407.23
03:34 ET31007.26
03:36 ET3297.26
03:38 ET22007.25
03:39 ET6007.25
03:41 ET8887.24
03:43 ET11007.26
03:45 ET13957.27
03:48 ET17117.29
03:50 ET8007.29
03:52 ET51667.265
03:54 ET43987.27
03:56 ET20277.29
03:57 ET60547.28
03:59 ET579907.3
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVIR
Atea Pharmaceuticals Inc
607.8M
14.4x
---
United StatesCHRS
Coherus BioSciences Inc
606.2M
-2.9x
---
United StatesITOS
Iteos Therapeutics Inc
741.7M
2.7x
---
United StatesICPT
Intercept Pharmaceuticals Inc
419.8M
-6.3x
---
United StatesAGEN
Agenus Inc
529.7M
-21.0x
---
United StatesVNDA
Vanda Pharmaceuticals Inc
632.1M
35.5x
---
As of 2022-07-04

Company Information

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The Company is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The Company is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. It is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The Company is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.

Contact Information

Headquarters
125 Summer Street, 16Th FloorBOSTON, MA, United States 02110
Phone
857-284-8891
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Jean-Pierre Sommadossi
Chief Financial Officer, Executive Vice President - Legal , Secretary
Andrea Corcoran
Executive Vice President, Chief Accounting Officer
Wayne Foster
Chief Development Officer
Janet Hammond
Chief Medical Officer
Maria Horga

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$607.8M
Revenue (TTM)
$285.4M
Shares Outstanding
83.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.51
Book Value
$8.54
P/E Ratio
14.4x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
12.5x
Operating Margin
22.97%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.